21:35 , Aug 3, 2018 |  BC Extra  |  Preclinical News

Mechanism identified behind thalidomide-induced birth defects

Researchers at Dana-Farber Cancer Institute uncovered the mechanistic pathway by which thalidomide and two related analogs cause severe fetal harm, answering a long-held question about the three teratogenic drugs now used as cancer therapies. The insight...
16:36 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Celgene planning regulatory submissions for Revlimid in indolent lymphoma on Phase III win

Celgene Corp. (NASDAQ:CELG) said Revlimid lenalidomide plus Rituxan rituximab met the primary endpoint of improving progression-free survival (PFS) vs. placebo plus Rituxan in the Phase III AUGMENT trial to treat relapsed or refractory follicular and...
18:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Celgene reports detailed data from missed Phase III of Revlimid combo for follicular lymphoma

Celgene Corp. (NASDAQ:CELG) reported detailed data from the Phase III RELEVANCE trial of Revlimid lenalidomide plus Rituxan rituximab to treat previously untreated follicular lymphoma. The data were presented at the American Society of Clinical Oncology...
18:24 , Apr 19, 2018 |  BC Extra  |  Preclinical News

Increased ubiquitination of EZH2 or ALK for cancer therapies

Papers published in Cell Reports and Journal of Medicinal Chemistry suggest that targeted degradation by increasing ubiquitination of proteins that promote cancer could be a more complete strategy to treat cancer than catalytic inhibition. As increased...
16:04 , Mar 26, 2018 |  BC Extra  |  Preclinical News

Bradner, Gray explore targeted degradation-based model systems

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray published a paper in Nature Chemical Biology demonstrating a generalizable target-specific protein degradation system that can be used to create preclinical models that offer better control...
16:01 , Mar 26, 2018 |  BC Innovations  |  Translation in Brief

Tagging out

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
19:09 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Celgene's Revlimid misses in Phase III for follicular lymphoma

Celgene Corp. (NASDAQ:CELG) said Revlimid lenalidomide plus Rituxan rituximab missed the co-primary endpoints of improving complete response/unconfirmed complete response rate at 120 weeks and progression-free survival (PFS) in the Phase III RELEVANCE trial to treat...
01:18 , Dec 13, 2017 |  BC Innovations  |  Distillery Techniques

Assay and screens

TECHNOLOGY: Cellular assays A microfluidics-based method for measuring mass accumulation rates (MARs) in single cells could help predict therapeutic responses in MM patients. The method involves introducing patient-derived sample cells into a suspended microchannel resonator (SMR)...
21:52 , Dec 1, 2017 |  BC Week In Review  |  Company News

ArcherDX to develop companion diagnostic for CC-122

ArcherDx Inc. (Boulder, Colo.) will develop and commercialize a companion diagnostic to identify diffuse B cell lymphoma patients who may best respond to CC-122 from Celgene Corp. (NASDAQ:CELG). CC-122 is a cancer pleiotropic pathway modifier...